<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Laura</forename><forename type="middle">B</forename><surname>Ramsey</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Research in Patient Services</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Division of Clinical Pharmacology</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Cincinnati Children&apos;s Hospital Medical Center</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="department" key="dep3">College of Medicine</orgName>
								<orgName type="institution">University of Cincinnati</orgName>
								<address>
									<settlement>Cincinnati</settlement>
									<region>Ohio</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><forename type="middle">M</forename><surname>Balis</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Childhood Cancer Research</orgName>
								<orgName type="institution">The Children&apos;s Hospital of Philadelphia</orgName>
								<address>
									<settlement>Philadelphia</settlement>
									<region>Pennsylvania</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maureen</forename><forename type="middle">M</forename><surname>O'brien</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Division of Oncology, Cancer and Blood Diseases Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kjeld</forename><surname>Schmiegelow</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Pediatrics and Adolescent Medicine</orgName>
								<orgName type="department" key="dep2">Institute of Clinical Medicine</orgName>
								<orgName type="department" key="dep3">Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">University Hospital Rigshospitalet</orgName>
								<orgName type="institution" key="instit2">University of Copenhagen</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jennifer</forename><forename type="middle">L</forename><surname>Pauley</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Pharmaceutical Department</orgName>
								<orgName type="institution">St. Jude Children&apos;s Research Hospital</orgName>
								<address>
									<settlement>Memphis</settlement>
									<region>Tennessee</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Archie</forename><surname>Bleyer</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Radiation Medicine</orgName>
								<orgName type="institution">Oregon Health and Science University</orgName>
								<address>
									<settlement>Portland</settlement>
									<region>Oregon</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brigitte</forename><forename type="middle">C</forename><surname>Widemann</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Pediatric Oncology Branch</orgName>
								<orgName type="department" key="dep2">Center for Cancer Research</orgName>
								<orgName type="institution">National Cancer Institute</orgName>
								<address>
									<settlement>Bethesda</settlement>
									<region>Maryland</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Askenazi</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Pediatric and Infant Center for Acute Nephrology</orgName>
								<orgName type="department" key="dep2">Professor of Pediatrics</orgName>
								<orgName type="institution">University of Alabama at Birmingham</orgName>
								<address>
									<settlement>Birmingham</settlement>
									<region>Alabama</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sharon</forename><surname>Bergeron</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution" key="instit1">Hyundai Cancer Institute</orgName>
								<orgName type="institution" key="instit2">Children&apos;s Hospital of Orange County</orgName>
								<address>
									<settlement>Orange</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anushree</forename><surname>Shirali</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Assistant Professor of Medicine</orgName>
								<orgName type="department" key="dep2">Section of Nephrology</orgName>
								<orgName type="institution">Yale University School of Medicine</orgName>
								<address>
									<settlement>New Haven, Connecticut</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Schwartz</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution" key="instit1">Medizinische Klinik mit Schwerpunkt H€ amatologie</orgName>
								<orgName type="institution" key="instit2">Onkologie und Tumorimmunologie</orgName>
								<orgName type="institution" key="instit3">Charit e Campus Benjamin Franklin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><forename type="middle">A</forename><surname>Vinks</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Research in Patient Services</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Division of Clinical Pharmacology</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Cincinnati Children&apos;s Hospital Medical Center</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="department" key="dep3">College of Medicine</orgName>
								<orgName type="institution">University of Cincinnati</orgName>
								<address>
									<settlement>Cincinnati</settlement>
									<region>Ohio</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jesper</forename><surname>Heldrup</surname></persName>
							<affiliation key="aff13">
								<orgName type="laboratory">Childhood Cancer and Research Unit</orgName>
								<orgName type="institution">University Children&apos;s Hospital</orgName>
								<address>
									<settlement>Lund</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Words</forename><surname>Key</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Creatinine</forename><forename type="middle">•</forename><surname>Methotrexate</surname></persName>
						</author>
						<author>
							<persName><forename type="first">•</forename><surname>Glucarpidase</surname></persName>
						</author>
						<author>
							<persName><surname>Leucovorin</surname></persName>
						</author>
						<title level="a" type="main">Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">B1FADE8979F6086F05B1B00304EBDFF2</idno>
					<idno type="DOI">10.1634/theoncologist.2017-0243</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acute kidney injury due to high-dose methotrexate (HDMTX) is a serious, life-threatening toxicity that can occur in pediatric and adult patients.</s><s>Glucarpidase is a treatment approved by the Food and Drug Administration for high methotrexate concentrations in the context of kidney dysfunction, but the guidelines for when to use it are unclear.</s><s>An expert panel was convened to provide specific, expert consensus guidelines for the use of glucarpidase in patients who develop HDMTXinduced nephrotoxicity and delayed methotrexate excretion.</s><s>The guideline provides recommendations to identify the population of patients who would benefit from glucarpidase rescue by more precisely defining the absolute methotrexate concentrations associated with risk for severe or life-threatening toxicity at several time points after the start of an HDMTX infusion.</s><s>For an HDMTX infusion 24 hours, if the 36-hour concentration is above 30 mM, 42-hour concentration is above 10 mM, or 48-hour concentration is above 5 mM and the serum creatinine is significantly elevated relative to the baseline measurement (indicative of HDMTX-induced acute kidney injury), glucarpidase may be indicated.</s><s>After a 36-to 42-hour HDMTX infusion, glucarpidase may be indicated when the 48-hour methotrexate concentration is above 5 mM.</s><s>Administration of glucarpidase should optimally occur within 48-60 hours from the start of the HDMTX infusion, because life-threatening toxicities may not be preventable beyond this time point.</s><s>The Oncologist 2018;23:52-61 Implications for Practice: Glucarpidase is a rarely used medication that is less effective when given after more than 60 hours of exposure to high-dose methotrexate, so predicting early which patients will need it is imperative.</s><s>There are no currently available consensus guidelines for the use of this medication.</s><s>The indication on the label does not give specific methotrexate concentrations above which it should be used.</s><s>An international group of experts was convened to develop a consensus guideline that was specific and evidence-based to identify the population of patients who would benefit from glucarpidase.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Nephrotoxicity induced by high-dose methotrexate (HDMTX) is a medical emergency because the renal excretion of methotrexate (MTX) is subsequently delayed, and the resulting prolonged exposure to high concentrations of the drug can cause severe and life-threatening toxicity.</s><s>The recombinant bacterial enzyme glucarpidase, which is approved by the Food and Drug Administration (FDA) for use in patients with delayed MTX excretion, is a rescue agent that cleaves MTX into inactive metabolites, providing an alternative route of elimination for the drug in patients with nephrotoxicity <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>.</s><s>A task force was assembled to develop specific, evidence-based guidelines for the use of glucarpidase in patients who develop HDMTXinduced nephrotoxicity and delayed MTX excretion, and the recommendations of this working group are reported herein.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HIGH-DOSE METHOTREXATE PHARMACOLOGY</head><p><s>Methotrexate is an antifolate that can be administered over a broad dose range (from 20 to 33,600 mg/m 2 ) <ref type="bibr" target="#b6">[7]</ref> but is only tolerable at higher doses when followed by the rescue agent leucovorin (5-formyltetrahydrofolate).</s><s>HDMTX is commonly regarded as doses exceeding 500 mg/m 2 infused over 2-36 hours, requiring supportive care (e.g., hyperhydration) and leucovorin rescue.</s><s>Doses and infusion times vary by indication (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>MTX is a competitive inhibitor of the enzyme dihydrofolate reductase (DHFR; Fig. <ref type="figure" target="#fig_1">1</ref>) and blocks the conversion of dihydrofolate to its active, chemically reduced tetrahydrofolate form, thus depleting the intracellular pool of tetrahydrofolates, which are required cofactors (single-carbon donors) for the synthesis of methionine, thymidine, and purines.</s><s>MTX is polyglutamated intracellularly, and in this form (MTXPG) can also directly inhibit enzymes in the purine/pyrimidine synthetic pathways.</s><s>Thymidylate synthase is the only folate-requiring enzyme that oxidizes its tetrahydrofolate cofactor to dihydrofolate, and active synthesis of thymidine is necessary for MTX to deplete intracellular tetrahydrofolates.</s></p><p><s>The anticancer and toxic effects of MTX are highly schedule-dependent and are determined by the duration of exposure to a threshold concentration of the drug.</s><s>The threshold concentration is tissue-and tumor-specific.</s><s>Prolonged continuous exposure to low concentrations of MTX can cause severe myelosuppression and other severe toxicities.</s><s>Leucovorin, the HDMTX rescue agent, provides an alternative source of tetrahydrofolate and counteracts MTX toxicity if administered, preferably within 42 hours of the start of the HDMTX infusion.</s><s>Leucovorin must compete with MTX for cell entry and polyglutamation (Fig. <ref type="figure" target="#fig_1">1</ref>), so it is less effective as a rescue agent at high MTX concentrations if it is not also present at an equipotent concentration.</s></p><p><s>Renal excretion of the parent drug is the primary route of elimination for HDMTX, accounting for approximately 70%-90% of MTX clearance <ref type="bibr" target="#b7">[8]</ref>.</s><s>MTX is a weak acid with limited solubility in acidic conditions (2 mM maximum solubility at pH 5).</s><s>Alkalinization of the urine has a greater impact on MTX solubility in urine than fluid hydration <ref type="bibr" target="#b8">[9]</ref>.</s><s>MTX solubility increases 10-fold by increasing the pH from 6 to 7 <ref type="bibr" target="#b9">[10]</ref>.</s><s>MTX is secreted and not reabsorbed by renal tubules, but tubular secretion is saturated at higher plasma concentrations and only plays a minor role in MTX elimination during and immediately after the HDMTX infusion <ref type="bibr" target="#b10">[11]</ref>.</s><s>MTX is 60% protein-bound, and glomerular filtration is limited to free drug.</s><s>Therefore, MTX clearance at high concentrations is less than the glomerular filtration rate (GFR).</s><s>MTX is also metabolized in the liver by aldehyde oxidase to 7-hydroxymethotrexate, which accounts for 5%-10% of MTX elimination <ref type="bibr" target="#b7">[8]</ref>.</s><s>There is substantial interpatient and intrapatient variability in the clearance of MTX, which ranges 10-fold (depending on dose, age, and infusion time) in patients with normal renal function after an HDMTX infusion <ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HDMTX-INDUCED ACUTE KIDNEY INJURY AND DELAYED MTX CLEARANCE</head><p><s>HDMTX-induced acute kidney injury (AKI) occurs during or shortly after the end of the infusion near the end of the steadystate plasma concentration (Fig. <ref type="figure" target="#fig_2">2</ref>) <ref type="bibr">[16]</ref>.</s><s>The AKI is manifested as a rise in serum creatinine (decrease in GFR), but urine output is usually maintained (nonoliguric) <ref type="bibr" target="#b16">[17]</ref>.</s><s>MTX clearance declines in proportion to the decrease in GFR, resulting in prolonged exposure to high MTX concentrations that may exceed the capacity of standard doses of leucovorin to rescue from the toxicity of MTX.</s><s>HDMTX-induced AKI that is associated with substantial reductions in MTX clearance occurs in 0.5%-1.0% of courses of 5 g/m 2 over 24 hours in children with acute lymphoblastic leukemia (ALL) <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref> and 1.8% of courses of 12 g/m 2 over 4 hours in children, adolescents, and young adults with osteosarcoma <ref type="bibr" target="#b19">[20]</ref>.</s><s>Approximately 2%-12% of adults treated with HDMTX develop nephrotoxicity <ref type="bibr" target="#b20">[21]</ref>.</s><s>HDMTX-induced AKI is reversible, and nearly all patients fully recover renal function.</s><s>The GFR of most patients with HDMTX-induced AKI returns to baseline values after AKI, although this can take weeks <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>.</s><s>The long-term consequences of HDMTX-induced AKI have not been fully investigated, but it is possible that nephron loss occurs after such injury, resulting in subsequent chronic kidney disease, as has been shown in other models of AKI <ref type="bibr" target="#b23">[24]</ref>.</s></p><p><s>Possible mechanisms of HDMTX-induced AKI include pHdependent precipitation of MTX in urine in the renal tubules <ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref>, reduced renal perfusion from afferent arteriolar vasoconstriction, or uptake of MTX into the renal tubules with direct tubular toxicity <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr">16]</ref>.</s><s>The osteosarcoma HDMTX regimen (8-12 g/m 2 over 4 hours), which has a higher incidence of HDMTX-induced AKI, as noted above, yields an end-of-infusion plasma MTX concentration of approximately 1,000 mM (1 mM) <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29]</ref>, and the simultaneous urine MTX concentration is approximately 10,000 mM (10 mM) <ref type="bibr" target="#b7">[8]</ref>, which approximates the solubility limit of MTX at pH 7. The timing of HDMTX-induced AKI and the effectiveness of alkalinization and volume expansion (fluid hydration) administered prior to, during, and after a HDMTX infusion at preventing HDMTX-induced AKI supports the view that MTX precipitation plays a role in this toxicity.</s><s>Documenting normal renal function prior to administering HDMTX and serial monitoring of serum creatinine before and at the end of HDMTX infusion are mandatory to detect HDMTX-induced AKI as early as possible.</s><s>An increase in serum creatinine of more than 50% within 24-36 hours from the pre-HDMTX baseline value has a sensitivity of 0.32 and a specificity of 0.99 for predicting delayed MTX elimination <ref type="bibr">[16]</ref>.</s><s>However, serum creatinine is a suboptimal biomarker of AKI, as creatinine rise may lag significantly from the time of the renal insult.</s><s>Elevated plasma MTX concentration may indicate HDMTX-induced AKI prior to a significant change in creatinine.</s><s>Thus, clinicians administering HDMTX should be familiar with the expected plasma MTX concentration at the various time points after infusion (supplemental online Tables <ref type="table" target="#tab_0">1 and 2</ref>).</s><s>After recovery of renal function (normal GFR), HDMTX therapy can generally be safely administered at full dose in pediatric and adult patients who previously experienced HDMTXinduced AKI or received glucarpidase <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b29">30]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>STRATEGIES TO PREVENT HDMTX-INDUCED AKI</head><p><s>In early studies of HDMTX, severe toxicity occurred in approximately 10% of patients with a 6% toxic mortality rate <ref type="bibr" target="#b30">[31]</ref>.</s><s>The incidence of severe, life-threatening toxicity after HDMTX therapy has been reduced to less than 1% by the implementation of supportive care measures to prevent HDMTX-induced AKI,  <ref type="figure" target="#fig_4">ABCC1-4</ref>) and breast cancer resistance protein <ref type="bibr" target="#b76">[79]</ref>, but their role in MTX clearance and efficacy is less well documented.</s><s>Passive diffusion plays a significant role during high-dose MTX (HDMTX) therapy.</s><s>Most of the MTX that enters the liver re-enters the blood circulation by enterohepatic circulation via the ABCC transporters, and only a small portion is excreted into the bile.</s><s>MTX interferes with the natural folate-homocysteine cycle and inhibits folate-dependent enzymes and pathways, including DHFR, TYMS, 5,10-methylenetetrahydrofolate reductase, and purine de novo synthesis.</s><s>This leads to a lack of reduced folate, inhibition of DNA synthesis, increased homocysteine and adenosine concentrations, and potentially lifethreatening toxicities [32, <ref type="bibr" target="#b77">80,</ref><ref type="bibr" target="#b78">81]</ref>.</s><s>Leucovorin (folinic acid) is essential for cellular rescue after HDMTX, and insufficient intracellular concentrations of leucovorin after HDMTX may cause life-threatening toxicities.</s><s>Intracellularly, the enzyme FPGS polyglutamates MTX by adding 2-6 glutamate residues, creating MTXPG, which increases intracellular retention as well as affinity for its target enzymes proportional to glutamyl chain lengths <ref type="bibr" target="#b79">[82]</ref><ref type="bibr" target="#b80">[83]</ref><ref type="bibr" target="#b81">[84]</ref><ref type="bibr" target="#b82">[85]</ref><ref type="bibr" target="#b83">[86]</ref>.</s></p><p><s>Abbreviations: 5-FP, 5-formylpteroate; ABC, ATP-binding cassette; ABCC, ABC subfamily C; CH 2 THF, 5,10-Methylenetetrahydrofolate; DAMPA, 4-deoxy-4-amino-N10-methylpteroic acid; DHF, dihydrofolate; DHFR, dihydrofolate reductase; dTMP, deoxythymidine monophosphate; dUMP, deoxyuridine monophosphate; FPGS, folylpolyglutamate synthetase; GLU, glutamate; LV, leucovorin, MTX, methotrexate; MTXPG, polyglutamated methotrexate; RFC, reduced folate carrier; SHMT1, serine hydroxymethyltransferase 1; THF, tetrahydrofolate; TYMS, thymidylate synthase.</s><s>Abbreviations: CI, confidence interval; GP, glucarpidase; HPLC, high pressure liquid chromatography; MTX, methotrexate.</s></p><p><s>including alkalinization of urine, fluid hydration with frequent monitoring of serum creatinine, and serial monitoring of plasma MTX concentrations to determine the dose and duration of leucovorin rescue <ref type="bibr" target="#b18">[19,</ref><ref type="bibr">[32]</ref><ref type="bibr" target="#b31">[33]</ref><ref type="bibr" target="#b32">[34]</ref>.</s><s>Urine pH should be documented to be above 7 prior to the start of a HDMTX infusion and should be maintained at this level until the plasma MTX concentration drops below the solubility threshold.</s><s>Urinary flow prior to, during, and after a HDMTX infusion should be maintained at least at 2,500 mL/m 2 per day (supplemental online Table <ref type="table">3</ref>) <ref type="bibr" target="#b33">[35]</ref>.</s><s>If urinary flow drops below 2,000 mL/m 2 per day, there is a higher risk for delayed MTX clearance <ref type="bibr" target="#b34">[36]</ref>.</s></p><p><s>The purpose of alkalinization of the urine and fluid hydration is to maximize the solubility of MTX in urine.</s><s>These measures do not enhance MTX clearance, which is largely dependent on glomerular filtration at high plasma MTX concentrations.</s><s>Once the plasma MTX concentration drops below 10 mM after infusion, the urine concentration is estimated to be an order of magnitude below the drug's solubility limit at pH 6; thus, alkalinization and hydration are less important as the plasma MTX concentration continues to decrease to the target level (typically 0.1 or 0.2 mM) at which leucovorin rescue can be stopped in patients with normal renal function.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>LEUCOVORIN RESCUE</head><p><s>Leucovorin and its primary circulating metabolite, 5-methyltetrahydrofolate, prevent the potentially severe and lifethreatening toxicities from HDMTX by providing a source of intracellular tetrahydrofolates that enter the folate cycle downstream of DHFR, which is inhibited by MTX.</s><s>However, these exogenous tetrahydrofolates must compete with MTX for cellular uptake via the reduced folate carrier and, once in the cell, for polyglutamylation, which enhances intracellular retention of folates and affinity for the target enzymes (Fig. <ref type="figure" target="#fig_1">1</ref>).</s><s>Therefore, leucovorin rescue is less effective at high MTX concentrations, especially when the MTX concentration exceeds 10 mM for 48 hours or longer.</s><s>The leucovorin dose must be increased in proportion to the MTX concentration when MTX clearance is delayed due to HDMTX-induced AKI.</s></p><p><s>Timing of MTX measurements and the dose and initiation of leucovorin rescue vary across different treatment regimens (Table <ref type="table" target="#tab_0">1</ref>) <ref type="bibr" target="#b8">[9]</ref>.</s><s>Leucovorin rescue usually starts 24-42 hours after the start of the HDMTX infusion and must not be delayed beyond 42-48 hours, even if the HDMTX infusion does not finish at the planned time.</s><s>Delaying the start of leucovorin rescue beyond 48 hours after the start of the HDMTX infusion significantly increases the risk for severe MTX toxicity <ref type="bibr" target="#b35">[37]</ref>.</s><s>Standard doses of leucovorin can be administered orally, but higher doses used when the MTX concentration is elevated must be administered intravenously because the absorption of leucovorin and other folates from the intestinal tract is carrier-mediated and saturable at doses above 40 mg.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GLUCARPIDASE BACKGROUND</head><p><s>Glucarpidase (carboxypeptidase G 2 or Voraxaze, BTG plc, London, UK, www.btgplc.com) is a recombinant bacterial enzyme that inactivates MTX and folates by hydrolyzing the glutamate moiety (Fig. <ref type="figure" target="#fig_3">3</ref>).</s><s>Carboxypeptidase G 1 (CPG 1 ) was isolated from Pseudomonas stutzeri in the 1970s.</s><s>Studies in mice and in a small number of patients revealed that administration of CPG 1 after MTX dosing prevented subsequent toxicity <ref type="bibr" target="#b36">[38]</ref>; however, the bacterial source was subsequently lost <ref type="bibr" target="#b37">[39]</ref>.</s><s>In the 1980s, carboxypeptidase G 2 (CPG 2 ) was isolated and purified from the Pseudomonas strain RS-16 and cloned into Escherichia coli <ref type="bibr" target="#b38">[40,</ref><ref type="bibr" target="#b39">41]</ref>.</s><s>Glucarpidase rapidly lowers the MTX concentration by cleaving MTX into two noncytotoxic metabolites, 4-deoxy-4amino-N10-methylpteroic acid (DAMPA) and glutamate, which are eliminated primarily by the liver (through the bile) and not by the kidney <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b40">42]</ref>.</s></p><p><s>Glucarpidase is provided as a lyophilized powder in vials containing 1,000 units and is administered in a single intravenous dose of 50 units/kg.</s><s>Dose-finding studies of glucarpidase were not conducted in humans, but this recommended dose has been shown to be safe and effective <ref type="bibr">[43]</ref>.</s><s>Glucarpidase may not be routinely stocked in pharmacies because of its high cost and infrequent use, so the drug should be ordered as soon as the need for its use is anticipated (https://www.btgplc.com/</s><s>products/specialty-pharmaceuticals/voraxaze-glucarpidase/).</s><s>Adverse reactions related to glucarpidase, including nausea/ vomiting, hypotension, paresthesia, flushing, and headache (mostly grade 2, according to the NCI Common Terminology Criteria for Adverse Events, version 3), were recorded each in less than 3% of patients <ref type="bibr" target="#b5">[6]</ref>.</s><s>Despite the potential immunogenicity related to the bacterial source of glucarpidase, hypersensitivity reactions were reported in &lt;1% of patients, but 17% of patients receiving one or two doses of glucarpidase developed antiglucarpidase antibodies <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b41">44,</ref><ref type="bibr" target="#b42">45]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GLUCARPIDASE PHARMACOLOGY</head><p><s>The pharmacokinetics of glucarpidase, which is an 83 kDa protein, were studied in the absence of MTX in eight healthy volunteers and in four subjects with severe renal dysfunction <ref type="bibr" target="#b44">[46]</ref>.</s><s>The molecular weight exceeds the threshold for glomerular filtration, so renal excretion is not likely to play a role in drug elimination.</s><s>In normal volunteers, the clearance was 7.5 mL/min; the volume of distribution was 3.6 L, which is comparable to plasma volume; and the half-life was 6 or 9 hours (depending on the drug assay method) and was not substantially different in patients with renal dysfunction <ref type="bibr">[43]</ref>.</s><s>Due to the large molecular size of glucarpidase, it does not enter cells or cross the blood-brain barrier.</s><s>Because of the limited distribution volume of glucarpidase, metabolism of tissue and intracellular MTX is reliant on diffusion of the drug back into circulation.</s><s>Glucarpidase cannot directly rescue the intracellular effects of MTXPG, although it can limit further kidney damage.</s><s>Thus, leucovorin is still required after glucarpidase to protect normal cells from MTX toxicity <ref type="bibr" target="#b45">[47]</ref>.</s></p><p><s>Glucarpidase rapidly metabolizes circulating MTX and reduces plasma MTX concentrations by &gt;95% within 15 minutes of administration <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b40">42,</ref><ref type="bibr" target="#b42">45]</ref>.</s><s>This catalytic effect on circulating MTX persists for 48 hours, but there can be a rebound of plasma MTX concentration as the activity of glucarpidase wanes and MTX redistributes to circulation from tissues <ref type="bibr" target="#b20">[21]</ref> (Fig. <ref type="figure" target="#fig_4">4</ref>).</s><s>However, the rebound plasma MTX concentration is typically substantially lower than the preglucarpidase MTX level <ref type="bibr" target="#b22">[23]</ref>.</s><s>Glucarpidase has a higher affinity for MTX (K m 8 mM) than for leucovorin (K m 120 mM) and 5-methyltetrahydrofolate (K m 35 mM), but in vivo the AUC 0-3h of 5-MeTHF drops by &gt;90% after administration of glucarpidase <ref type="bibr" target="#b38">[40,</ref><ref type="bibr" target="#b39">41]</ref>.</s></p><p><s>Intravenously administered glucarpidase mediates rapid degradation of MTX and, as such, may have a role in limiting further nephrotoxicity; however, by itself, glucarpidase does not impact the normalization of kidney dysfunction <ref type="bibr" target="#b22">[23]</ref>.</s><s>Successful intrathecal administration of glucarpidase has been reported in a limited number of patients who experienced an accidental intrathecal MTX overdose <ref type="bibr" target="#b41">[44,</ref><ref type="bibr" target="#b46">48]</ref>; in contrast, in this emergency scenario, intrathecal administration of leucovorin should strictly be avoided <ref type="bibr" target="#b47">[49]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INDICATIONS FOR GLUCARPIDASE THERAPY</head><p><s>Treatment with glucarpidase is indicated for patients with HDMTX-induced AKI and delayed MTX elimination leading to potentially toxic plasma MTX concentrations.</s><s>The FDA has approved a dose of 50 units/kg for the treatment of toxic plasma methotrexate concentrations (&gt;1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.</s><s>But the limitations of use indicate that it should not be used in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within two standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to MTX <ref type="bibr" target="#b5">[6]</ref>.</s></p><p><s>The goal of this task force was to identify the population of patients who would benefit from glucarpidase rescue by more precisely defining the absolute MTX concentrations that put patients at risk for severe or life-threatening toxicity at specific time points after the start of the HDMTX infusion based on reported experience with HDMTX infusions.</s><s>The duration of time above the threshold MTX concentration for various tissues was considered when determining the concentration cutoffs at each time point.</s><s>We provide guidance for many of the time points that are routinely monitored in clinical practice (Fig. <ref type="figure" target="#fig_5">5</ref>).</s><s>Consulting with an experienced oncologist, nephrologist, or clinical pharmacist who is familiar with managing patients treated with HDMTX infusions is recommended if the patient has prior HDMTX-induced AKI or a GFR &lt;75 mL/min/1.73</s><s>m 2 .</s><s>Administration of glucarpidase should optimally occur within 48-60 hours from the start of the HDMTX infusion, because life-threatening toxicities may not be preventable beyond this time point.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1-8 g/m 2 MTX Infused over 24-42 Hours</head><p><s>For a 24-hour infusion, a plasma MTX concentration &gt;120 mM (54.5 mg/mL) at the end of the infusion or a creatinine increase 50% over baseline warrants additional monitoring at 36 hours.</s><s>If the 36-hour MTX concentration is above 30 mM (13.6 mg/mL), the 42-hour MTX concentration is above 10 mM (4.54 mg/mL), or the 48-hour concentration is above 5 mM (2.27 mg/ mL) and the serum creatinine is elevated relative to the baseline measurement (indicative of HDMTX-induced AKI), glucarpidase may be indicated.</s><s>After a 36-42 hour HDMTX infusion, administration of glucarpidase may be indicated when the 48-hour MTX concentration is above 5 mM.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>8-12 g/m 2 MTX Infused over 6 Hours</head><p><s>A plasma MTX concentration &gt;1500 mM (681 mg/mL) at the end of the infusion warrants additional monitoring at 24 hours.</s><s>If the 24-hour concentration is above 50 mM (22.7 mg/mL), the 36-hour concentration is above 30 mM (13.6 mg/mL), the 42-hour MTX concentration is above 10 mM (4.54 mg/mL), or the 48-hour concentration is above 5 mM (2.27 mg/mL) and the serum creatinine is elevated relative to the baseline measurement (indicative of HDMTX-induced AKI), administration of glucarpidase may be indicated.</s></p><p><s>There is a potential for falsely elevated plasma MTX concentration during or shortly after the end of the HDMTX infusion due to contamination if the specimen is drawn from the same lumen of the central venous catheter through which the drug was infused.</s><s>If the plasma MTX concentration is elevated, but</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GLUCARPIDASE ADMINISTRATION RECOMMENDATIONS</head><p><s>Leucovorin should be dosed according to the standard guidelines (Fig. <ref type="figure" target="#fig_6">6</ref>) until glucarpidase can be given.</s><s>Some regimens use the following equation to calculate the leucovorin dose (in mg) rather than the leucovorin nomogram in Figure <ref type="figure" target="#fig_6">6</ref> if the plasma MTX concentration is &gt;5 mM: plasma MTX concentration (mM) 3 body weight (kg).</s><s>If glucarpidase is administered within 2 hours of the last dose of leucovorin, it will cleave the leucovorin as well as the MTX.</s><s>Leucovorin should not be administered until 2 hours after a dose of glucarpidase because it may interfere with glucarpidase-mediated metabolism of MTX.</s></p><p><s>Leucovorin and MTX are racemic mixtures of two stereoisomers, and only the levo (L) enantiomer is recognized by most folate carriers and enzymes that utilize folates as a cofactor or are inhibited by MTX or MTXPG.</s><s>The active levo enantiomer of leucovorin (levoleucovorin calcium) is FDA-approved for use as a MTX rescue agent.</s><s>Glucarpidase cleavage of MTX and tetrahydrofolates is less stereo-specific because the cleavage site does not involve the chiral carbon.</s><s>Glucarpidase should be administered according to the package insert.</s><s>If less than the full dose of 50 units/kg is all that is available, any amount that is available should be given, as lower doses may be effective <ref type="bibr" target="#b21">[22]</ref>.</s><s>Leucovorin rescue should be reinitiated no sooner than 2 hours after glucarpidase administration.</s><s>Repeat administration of glucarpidase within 48 hours of the first dose during the same MTX course is not recommended due to decreased efficacy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MEASUREMENT OF MTX AFTER GLUCARPIDASE THERAPY</head><p><s>Most clinical laboratories measure plasma MTX with an immunoassay method and not by a more specific high pressure liquid chromatography (HPLC) method <ref type="bibr" target="#b48">[50]</ref>.</s><s>Immunoassay methods detect MTX and its metabolites DAMPA and, to a varying extent, 7-hydroxymethotrexate.</s><s>After glucarpidase administration, essentially all circulating MTX is converted into the nontoxic metabolite DAMPA and other metabolites <ref type="bibr" target="#b3">[4]</ref> (Fig. <ref type="figure" target="#fig_3">3</ref>), but an immunoassay method that does not distinguish between MTX and DAMPA overestimates the true MTX concentration.</s><s>With an HPLC method that chromatographically separates MTX from DAMPA, the plasma MTX concentration usually drops by &gt;95% by 15 minutes after glucarpidase.</s><s>The half-life of DAMPA is approximately 9-10 hours, resulting in immunoassay interference and an inability to accurately quantify the MTX concentration for approximately 48 hours after glucarpidase.</s><s>This limitation of the MTX immunoassay methods after glucarpidase therapy should be recognized and communicated between clinical and laboratory personnel.</s><s>Another factor to consider is the potential rebound of MTX concentrations more than 48 hours after glucarpidase administration (Fig. <ref type="figure" target="#fig_4">4</ref>) due to release of MTX from tissue stores; therefore, continued monitoring of MTX concentrations and administration of leucovorin is very important in these patients <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b40">42,</ref><ref type="bibr" target="#b49">51,</ref><ref type="bibr" target="#b50">52]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>GUIDELINES FOR LEUCOVORIN USE AFTER GLUCARPIDASE THERAPY</head><p><s>Due to the large quantities of calcium, the infusion time of leucovorin at doses &gt;200-500 mg (or the patient's body surface area (BSA) 3 50) should be over 1-2 hours.</s><s>To avoid excessive calcium concentrations, leucovorin can be substituted with calcium levofolinate or disodium levofolinate, which contain the active L-form of leucovorin, allowing the dose of leucovorin to be reduced by 50% compared with the racemic form.</s><s>Disodium levofolinate can be given as a bolus dose and thus gives a faster clinical effect.</s><s>Treatment with leucovorin should be continued until the plasma MTX concentration is below the threshold prescribed by the treatment protocol (e.g., below 0.1-0.2</s><s>mM).</s><s>The minimal single dose of leucovorin is 15 mg/m 2 per dose.</s><s>The minimal single dose of calcium or disodium levofolinate is 7.5 mg/m 2 per dose.</s></p><p><s>Leucovorin rescue should be restarted 2 hours after the administration of glucarpidase at the dose based on the MTX level prior to glucarpidase therapy.</s><s>Because most institutions do not use an HPLC assay to specifically quantify MTX levels after glucarpidase administration, leucovorin rescue will be based on the MTX plasma concentration measured with the clinical immunoassay method, which measures MTX and its metabolites.</s><s>Leucovorin should be administered for at least 48 hours after glucarpidase because of the MTX reentering the bloodstream from the tissues (Fig. <ref type="figure" target="#fig_4">4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Alternatives to Glucarpidase Therapy</head><p><s>There are scant data to directly compare the efficacy of glucarpidase with other modalities of lowering MTX plasma concentrations <ref type="bibr" target="#b51">[53]</ref>, including intermittent and continuous hemodialysis, peritoneal dialysis, charcoal hemoperfusion, and increasing elimination via enterohepatic circulation using enteral binding agents like oral cholestyramine.</s><s>Hemodialysis and hemodiafiltration can clear MTX that is free in the plasma.</s></p><p><s>Given the relatively high volume of distribution and protein binding of MTX, a rebound of free MTX occurs when dialysis is stopped <ref type="bibr" target="#b52">[54]</ref><ref type="bibr" target="#b53">[55]</ref><ref type="bibr" target="#b54">[56]</ref>.</s><s>In situations in which glucarpidase is not available, when patients have very high MTX concentrations, the risks of hemodialysis and/or high dose continuous veno-venous hemodiafiltration are low compared with the potential benefit of providing enhanced MTX clearance.</s><s>Thymidine, which counteracts the effects of MTX through the restoration of DNA synthesis, did show promising results in clinical trials in a small number of patients but has been discontinued and is unavailable for investigational use <ref type="bibr" target="#b4">[5]</ref>.</s></p><p><s>High-dose leucovorin rescue has over the years been used for delayed MTX clearance when CPG 1 and CPG 2 were not easily available <ref type="bibr" target="#b55">[57]</ref>.</s><s>It is still the best option when glucarpidase is not available within 60 hours from the start of the HDMTX infusion.</s><s>However, unnecessarily high doses of leucovorin should be avoided, as treatment failures in association with higher leucovorin doses or "over-rescue" have been reported in pediatric patients with ALL and osteosarcoma <ref type="bibr" target="#b56">[58,</ref><ref type="bibr" target="#b57">59]</ref>.</s><s>Leucovorin is a storage vitamin, and excessive rescue could thus interfere with the MTX efficacy at the next HDMTX course <ref type="bibr" target="#b58">[60]</ref>.</s><s>Therefore, glucarpidase has increasingly come to the fore in the management and prevention of HDMTX-induced AKI.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effect of Age on MTX-Induced Nephrotoxicity</head><p><s>Adults generally do not tolerate HDMTX as well as children, and MTX pharmacokinetic parameters are dependent on age <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b59">61,</ref><ref type="bibr" target="#b60">62]</ref>.</s><s>The available pharmacokinetic data in adults are not as abundant as in children.</s><s>One protocol reduces the MTX dose based on the GFR in elderly patients with central nervous system lymphoma, which resulted in similar toxicities compared with patients with normal renal function <ref type="bibr" target="#b61">[63]</ref>.</s><s>However, in most contemporary adult ALL protocols, there is no dose reduction.</s><s>In a retrospective analysis including 649 HDMTX treatment cycles in 194 adult patients, advanced age was significantly associated with delayed MTX elimination and grade 2-4 renal toxicity <ref type="bibr" target="#b62">[64]</ref>.</s><s>In addition, elderly cancer patients are more likely to have some degree of baseline renal dysfunction that can be exacerbated by MTX <ref type="bibr" target="#b63">[65]</ref>.</s><s>Of 749 patients aged 1-45 years old treated by the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-2008 protocol, the 61 adult standard-or intermediate-risk patients who received 8 courses of HDMTX each and the 31 high-risk patients who received 6 courses demonstrated similar toxicities to the children treated on the same protocol <ref type="bibr" target="#b18">[19]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Concomitant Medications</head><p><s>As MTX-induced nephrotoxicity is closely tied to MTX clearance, reducing the risk of AKI from other nephrotoxic medications is imperative.</s><s>Each potential nephrotoxic medication should be carefully evaluated, and the risk and benefits of stopping this medication should be individualized.</s><s>Studies in pediatrics have clearly shown that the AKI can nearly be prevented with judicious use of nephrotoxic medications <ref type="bibr" target="#b64">[66]</ref>.</s><s>In addition, increased exposure to 7-hydroxymethotrexate has been reported in association with pantoprazole <ref type="bibr" target="#b65">[67]</ref>.</s><s>Concomitant use of medications that can interfere with MTX elimination, such as proton pump inhibitors and nonsteroidal antiinflammatory drugs, should be avoided <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b66">[68]</ref><ref type="bibr" target="#b67">[69]</ref><ref type="bibr" target="#b68">[70]</ref><ref type="bibr" target="#b69">[71]</ref><ref type="bibr" target="#b70">[72]</ref><ref type="bibr" target="#b71">[73]</ref><ref type="bibr" target="#b72">[74]</ref><ref type="bibr" target="#b73">[75]</ref>.</s><s>Even food (e.g., licorice <ref type="bibr" target="#b74">[76]</ref>) and beverages (soft drinks, often sweetened with licorice extract) with low pH have been suspected to affect the MTX clearance.</s><s>Since the introduction of 5-hydroxytryptamine (5HT3) receptor antagonists, emesis is not a problem during HDMTX and nowadays unlikely to be linked to AKI.</s></p><p><s>Trimethroprim-sulfamethoxazole is generally used as Pneumocystis jiroveci prophylaxis during ALL therapy <ref type="bibr" target="#b75">[77]</ref>, and there has been a worry that it could interfere with MTX pharmacokinetics and/or efficacy.</s><s>However, it does not seem to interfere with HDMTX pharmacokinetics <ref type="bibr">[78]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FURTHER RESEARCH NECESSARY</head><p><s>Given the paucity of published pharmacokinetic data in adults, it is difficult to determine whether the present recommendations, which are primarily based on pediatric experiences, adequately apply to adult patients.</s><s>Thus, pharmacokinetic data in adult patients should be prospectively collected and analyzed and include patients with HDMTX-induced AKI and patients receiving glucarpidase treatment.</s><s>These data are being collected in adults in Denmark (personal communication with Nina Toft, Adult NOPHO ALL-2008 coordinator).</s><s>Additional studies on the effect of comedications on HDMTX pharmacokinetics are also needed, because existing data are based mostly on single case reports.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p><s>The expert panel was able to come to consensus, providing specific MTX concentrations above which glucarpidase is strongly recommended.</s><s>Implementation of the recommendations in this guideline may help reduce the incidence of lifethreatening HDMTX-induced toxicities.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p><s>The authors of this guideline were selected to represent a diverse group of clinical providers with a range of expertise, including adult and pediatric oncologists, nephrologists, pharmacists, clinical pharmacologists, and a nurse.</s><s>The group met virtually three times and once in person.</s><s>The organizer, Dr. Ramsey, first provided evidence to the group for consideration and generated a draft flow chart.</s><s>Changes were made to the guideline iteratively until the group reached consensus.</s><s>JLP acknowledges support by a Cancer Center Support Grant (CA21765) from the National Cancer Institute (NCI) and by the American Lebanese Syrian Associated Charities (ALSAC).</s><s>We are grateful to Tomoyuki Mizuno for performing methotrexate pharmacokinetic analysis.</s><s>We are thankful to Dr. Kenneth Carson and Suhong Luo at Washington University, St. Louis, for providing methotrexate concentrations at specified time points adapted from previously published analyses.</s><s>We are also thankful to Holly Ward for coordinating the in-person meeting in Cincinnati.</s><s>This was an investigator-initiated project designed and executed by the authors.</s><s>Funding support was provided in the form of an educational grant from BTG, International (the manufacturer of glucarpidase) to AAV and LBR.</s><s>Sponsor representatives were not present during any discussions of the algorithm or manuscript development.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Correspondence: Laura B.Ramsey, Ph.D., Pharmacy Research, Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 6018, Cincinnati, Ohio 45229, USA.</s><s>Telephone: 513-803-8963; e-mail: laura.ramsey@cchmc.org</s><s>Received May 23, 2017; accepted for publication September 13, 2017; published Online First on October 27, 2017.</s><s>http://dx.doi.org/10.1634/theoncologist.2017-0243</s><s>The Oncologist 2018;23:52-61 www.TheOncologist.com</s><s>O c AlphaMed Press 2017 New Drug Development and Clinical Pharmacology</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>The cellular entry of MTX is mediated primarily by the ubiquitously expressed RFC, encoded by the human solute carrier family 19 member 1 (SLC19A1) gene on chromosome 21.Other influx and efflux mechanisms include ABC transporters (specifically ABCC1-4) and breast cancer resistance protein<ref type="bibr" target="#b76">[79]</ref>, but their role in MTX clearance and efficacy is less well documented.</s><s>Passive diffusion plays a significant role during high-dose MTX (HDMTX) therapy.</s><s>Most of the MTX that enters the liver re-enters the blood circulation by enterohepatic circulation via the ABCC transporters, and only a small portion is excreted into the bile.</s><s>MTX interferes with the natural folate-homocysteine cycle and inhibits folate-dependent enzymes and pathways, including DHFR, TYMS, 5,10-methylenetetrahydrofolate reductase, and purine de novo synthesis.</s><s>This leads to a lack of reduced folate, inhibition of DNA synthesis, increased homocysteine and adenosine concentrations, and potentially lifethreatening toxicities [32,<ref type="bibr" target="#b77">80,</ref><ref type="bibr" target="#b78">81]</ref>.</s><s>Leucovorin (folinic acid) is essential for cellular rescue after HDMTX, and insufficient intracellular concentrations of leucovorin after HDMTX may cause life-threatening toxicities.</s><s>Intracellularly, the enzyme FPGS polyglutamates MTX by adding 2-6 glutamate residues, creating MTXPG, which increases intracellular retention as well as affinity for its target enzymes proportional to glutamyl chain lengths<ref type="bibr" target="#b79">[82]</ref><ref type="bibr" target="#b80">[83]</ref><ref type="bibr" target="#b81">[84]</ref><ref type="bibr" target="#b82">[85]</ref><ref type="bibr" target="#b83">[86]</ref>.Abbreviations: 5-FP, 5-formylpteroate; ABC, ATP-binding cassette; ABCC, ABC subfamily C; CH 2 THF, 5,10-Methylenetetrahydrofolate; DAMPA, 4-deoxy-4-amino-N10-methylpteroic acid; DHF, dihydrofolate; DHFR, dihydrofolate reductase; dTMP, deoxythymidine monophosphate; dUMP, deoxyuridine monophosphate; FPGS, folylpolyglutamate synthetase; GLU, glutamate; LV, leucovorin, MTX, methotrexate; MTXPG, polyglutamated methotrexate; RFC, reduced folate carrier; SHMT1, serine hydroxymethyltransferase 1; THF, tetrahydrofolate; TYMS, thymidylate synthase.</s></p></div></figDesc><graphic coords="3,69.79,58.79,215.28,331.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Change in serum creatinine (A) and plasma methotrexate (B) concentrations relative to the start of the high-dose methotrexate infusion (time 0) in pediatric patients with acute lymphoblastic leukemia (ALL) receiving 5 g/m 2 over 24 hours on the Nordic Society of Paediatric Haematology and Oncology ALL-2008 protocol who also received GP.</s><s>Their measurements prior to glucarpidase (blue) and after glucarpidase (green) are shown relative to the predicted mean and 95% CI for patients receiving the same MTX dose (orange lines).Abbreviations: CI, confidence interval; GP, glucarpidase; HPLC, high pressure liquid chromatography; MTX, methotrexate.</s></p></div></figDesc><graphic coords="3,311.70,58.79,228.24,240.64" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Methotrexate is cleaved into two noncytotoxic metabolites, DAMPA and glutamic acid, by CPDG 2 .Abbreviations: CPDG 2 , glucarpidase; DAMPA, 4-deoxy-4-amino-N10-methylpteroic acid.</s></p></div></figDesc><graphic coords="4,310.85,58.79,229.68,166.72" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4 .</head><label>4</label><figDesc><div><p><s>Figure 4. Concentrations of MTX and SCr in a patient enrolled on the Nordic Society of Paediatric Haematology and Oncology acute lymphoblastic leukemia 2008 protocol treated with glucarpidase following a 5 g/m 2 dose of MTX over 24 hours.</s><s>The HPLC measurement of MTX (blue line) is more accurate than the FPIA measurement of MTX (green line) for the 48 hours following the administration of glucarpidase at hour 41.</s><s>The HPLC measurement shows a rebound of the MTX concentrations from hour 60 to hour 96.</s><s>The SCr increased during the 24-hour infusion and remained high for several days following the glucarpidase administration.</s><s>The FPIA and HPLC measurements were performed by Stein Bergan at the Department of Pharmacology, Rikshospitalet, Oslo, Norway.Abbreviations: conc, concentration; FPIA, fluorescence polarization immunoassay; HPLC, high pressure liquid chromatography; MTX, methotrexate; SCr, serum creatinine.</s></p></div></figDesc><graphic coords="5,310.28,58.79,230.76,157.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5 .</head><label>5</label><figDesc><div><p><s>Figure 5. Treatment with glucarpidase may be indicated in the case of excessively high MTX concentrations and rising creatinine.</s><s>Time points indicated are after the start of the infusion and are not required measurement times.</s><s>Guidance is provided for time points that are routinely measured in clinical practice.</s><s>Renal toxicity grade 31 is according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4. Concentrations in mM can be converted to mg/mL by dividing by 2.2005.</s><s>120 mM 5 54.5 mg/mL, 50 mM 5 22.7 mg/mL, 30 mM 5 13.6 mg/mL, 10 mM 5 4.54 mg/mL, and 5 mM 5 2.27 mg/mL.</s><s>*Urine pH &gt;7, urine output &gt;2.5L/m 2 per day, emesis control.</s><s>† Hours are indicated after infusion start.</s><s>Abbreviations: Cr, serum creatinine; GFR, glomerular filtration rate; HDMTX, high-dose methotrexate; LV, leucovorin (folinic acid, citrovorum factor, 5-methyltetrahydrofolate); MTX, methotrexate; [MTX], plasma methotrexate concentration.</s></p></div></figDesc><graphic coords="6,134.19,58.79,334.80,466.08" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 6 .</head><label>6</label><figDesc><div><p><s>Figure 6.</s><s>Standard leucovorin nomogram used in the U.S. Glucarpidase use may be indicated when MTX concentrations are within the shaded area.Abbreviation: MTX, methotrexate.</s></p></div></figDesc><graphic coords="7,122.17,58.79,358.92,243.04" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Common high-dose MTX regimens</s></p></div></figDesc><table><row><cell>Indication</cell><cell>ALL</cell><cell>Osteosarcoma</cell><cell>Lymphoma</cell></row><row><cell>HDMTX dose</cell><cell>1-5 g/m 2</cell><cell>8-12 g/m 2</cell><cell>1-8 g/m 2</cell></row><row><cell>Infusion duration</cell><cell>24-36 h</cell><cell>4 h</cell><cell>2-6 h</cell></row><row><cell>Leucovorin start time</cell><cell>42 h</cell><cell>24 h</cell><cell>18-24 h</cell></row><row><cell>MTX monitoring times a</cell><cell>24 h, (36 h), 42 h, 48 h</cell><cell>24 h, 48 h, 72 h</cell><cell>24 h, 48 h, 72 h</cell></row><row><cell cols="4">a Most hospitals monitor plasma MTX concentrations until MTX 0.1-0.2 mM. In ALL patients, 36 h concentrations are occasionally monitored.</cell></row><row><cell cols="3">Abbreviations: ALL, acute lymphoblastic leukemia; HDMTX, high-dose methotrexate; MTX, methotrexate.</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="59">www.TheOncologist.com O c AlphaMed Press 2017</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="61">www.TheOncologist.com O c AlphaMed Press 2017</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Renal dysfunction during and after high-dose methotrexate</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Chamberlain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="599" to="604" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The enzymatic hydrolysis of folate analogues</title>
		<author>
			<persName><forename type="first">P</forename><surname>Goldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Levy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Pharmacol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="2265" to="2270" />
			<date type="published" when="1968">1968</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The enzymatic hydrolysis of methotrexate and folic acid</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Goldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">242</biblScope>
			<biblScope unit="page" from="2933" to="2938" />
			<date type="published" when="1967">1967</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-n 10-methylpteroic acid</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Widemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pharmacol Exp Ther</title>
		<imprint>
			<biblScope unit="volume">294</biblScope>
			<biblScope unit="page" from="894" to="901" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Understanding and managing methotrexate nephrotoxicity</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Widemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Adamson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Oncologist</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="694" to="703" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Voraxaze (glucarpidase) package insert</title>
		<author>
			<persName><surname>Btg International</surname></persName>
		</author>
		<author>
			<persName><surname>Inc</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>BTG International, Inc</publisher>
			<pubPlace>Brentwood, TN</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: Results of National Cancer Institute/Children&apos;s Cancer Group trials CCG-191P, CCG-134P and CCG-144P</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Nathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Whitcomb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Wolters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="2488" to="2504" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: A concurrent analysis of the serum and urine concentration data</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fukuhara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Morikawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pharm Ther</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="677" to="684" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">Philadelphia</title>
		<author>
			<persName><forename type="first">R</forename><surname>Messmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Allegra</forename><forename type="middle">C</forename><surname>Antifolates</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2001">2001</date>
			<publisher>Lippincott Williams &amp; Wilkins</publisher>
			<biblScope unit="page" from="139" to="184" />
			<pubPlace>PA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma</title>
		<author>
			<persName><forename type="first">O</forename><surname>Mir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ropert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Babinet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1059" to="1063" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">PharmGKB summary: Methotrexate pathway</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Mikkelsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Thorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenet Genomics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">679</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Genomewide study of methotrexate clearance replicates SLCO1B1</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Ramsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Panetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="898" to="904" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Ramsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Bruun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1" to="8" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Wall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gajjar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Link</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">221</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">High-dose methotrexate: On the relationship of methotrexate elimination time vs renal function and serum methotrexate levels</title>
		<author>
			<persName><forename type="first">T</forename><surname>Pignon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lacarelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Duffaud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="420" to="424" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note>Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="311" to="320" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Drug-induced crystal nephropathy: An update</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Yarlagadda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Perazella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Drug Saf</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="147" to="158" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pauley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Molinelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="4321" to="4330" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Svahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mellgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Harila-Saari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page">e26395</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Widemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Balis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kempf-Bielack</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="2222" to="2232" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: Clinical and pharmacologic factors affecting outcome</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Widemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Balis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="3979" to="3986" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1518" to="1522" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Widemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Jayaprakash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacotherapy</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="427" to="439" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Acute kidney injury and chronic kidney disease as interconnected syndromes</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Chawla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Eggers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Star</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="58" to="66" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Stoller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chabner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page">534</biblScope>
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lankelma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Der Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ramaekers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="133" to="142" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Acute methotrexate-induced crystal nephropathy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Garneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Riopel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Isenring</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="2691" to="2693" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Methotrexate administered by 6-h and 24-h infusion: A pharmacokinetic comparison</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Borsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Moe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="33" to="35" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Methotrexate pharmacokinetics and survival in osteosarcoma</title>
		<author>
			<persName><forename type="first">I</forename><surname>Aquerreta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Aldaz</surname></persName>
		</author>
		<author>
			<persName><surname>Gir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="52" to="58" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol</title>
		<author>
			<persName><forename type="first">N</forename><surname>Toft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Birgens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Abrahamsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="404" to="412" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Toxicity associated with combination chemotherapy for osteosarcoma: A report of the cooperative osteosarcoma study (COSS 80)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ahmad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Bleyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>J€ Urgens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Beron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Winkler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cancer Res Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="14" to="18" />
			<date type="published" when="1978">1978. 1983</date>
		</imprint>
	</monogr>
	<note>Arch Intern Med</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7)</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Allegra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Boarman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="3574" to="3578" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Advances in individual prediction of methotrexate toxicity: A review</title>
		<author>
			<persName><forename type="first">K</forename><surname>Schmiegelow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="489" to="503" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Theoretically required urinary flow during high-dose methotrexate infusion</title>
		<author>
			<persName><forename type="first">K</forename><surname>Sasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fujimoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="9" to="13" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Patient characteristics associated with high-risk methotrexate concentrations and toxicity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Relling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fairclough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ayers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1667" to="1672" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Rescue&quot; techniques in cancer chemotherapy: Use of leucovorin and other rescue agents after methotrexate treatment</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Bertino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Oncol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="203" to="216" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity</title>
		<author>
			<persName><forename type="first">B</forename><surname>Chabner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Johns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bertino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">239</biblScope>
			<biblScope unit="page" from="395" to="397" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Adamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Balis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Mccully</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1359" to="1364" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Minton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Atkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Sherwood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bacteriol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="1222" to="1227" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Sherwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Melton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Alwan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Biochem</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="page" from="447" to="453" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Borner</surname></persName>
		</author>
		<ptr target="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125327Orig1s000SumR.pdf.Accessed" />
	</analytic>
	<monogr>
		<title level="m">Application Number 125327Orig1s000. U.S. Food and Drug Administration</title>
				<imprint>
			<date type="published" when="2007-01-12">2007. January 12. 2012. December 5, 2016</date>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1299" to="1308" />
		</imprint>
		<respStmt>
			<orgName>Center for Drug Evaluation and Research</orgName>
		</respStmt>
	</monogr>
	<note>The Oncologist</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Weihrauch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bode</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="2139" to="2143" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Buchen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ngampolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Melton</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure</title>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="480" to="487" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function</title>
		<author>
			<persName><forename type="first">M</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Balan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="279" to="284" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Carboxypeptidase G2 rescue after high-dose methotrexate</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Deangelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="2145" to="2149" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Widemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Balis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shalabi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="1557" to="1559" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Intrathecal leucovorin after intrathecal methotrexate overdose</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Jardine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Ingram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Bleyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="302" to="304" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Evaluation of clinical assays for measuring high-dose methotrexate in plasma</title>
		<author>
			<persName><forename type="first">F</forename><surname>Albertioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rask</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eksborg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="39" to="44" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Widemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Balis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Murphy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="2125" to="2134" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Effective clearance of methotrexate using high-flux hemodialysis membranes</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Wall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Johansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Molony</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="846" to="854" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">What is the best therapy for toxicity in the setting of methotrexate-associated acute kidney injury: High-flux hemodialysis or carboxypeptidase G2?</title>
		<author>
			<persName><forename type="first">N</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Shirali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Dial</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="226" to="226" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Hemoperfusion for methotrexate removal</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Reich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Krumlovsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="351" to="355" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Relling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">B</forename><surname>Stapleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ochs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="884" to="888" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Effective removal of methotrexate by high-flux hemodialysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Saland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Leavey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Bash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Nephrol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="825" to="829" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">High-dose leucovorin as sole therapy for methotrexate toxicity</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Flombaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Meyers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1589" to="1589" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Progression of osteosarcoma after high-dose methotrexate: Over-rescue by folinic acid</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Cohen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="579" to="581" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Sk€ Arby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Heldrup</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1955" to="1962" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sterba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dusek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Demlova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Folate overrescue&quot; concept revisited</title>
				<imprint>
			<date type="published" when="2006">2006</date>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="692" to="700" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Csordas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hegyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">T</forename><surname>Eipel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Drugs</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="189" to="197" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy</title>
		<author>
			<persName><forename type="first">G</forename><surname>Bacci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Longhi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Rep</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="851" to="858" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma</title>
		<author>
			<persName><forename type="first">K</forename><surname>Jahnke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="445" to="449" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">High incidence of methotrexate associated renal toxicity in patients with lymphoma: A retrospective analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Butler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1345" to="1349" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Chemotherapy-associated renal dysfunction</title>
		<author>
			<persName><forename type="first">V</forename><surname>Sahni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Choudhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ahmed</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Nephrol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="450" to="462" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">KDIGO clinical practice guideline for acute kidney injury</title>
	</analytic>
	<monogr>
		<title level="j">Kidney Int Suppl</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="138" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate</title>
		<author>
			<persName><forename type="first">U</forename><surname>Tr€ Oger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>St€ Otzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Martens-Lobenhoffer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">324</biblScope>
			<biblScope unit="page">1497</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Concepts in use of highdose methotrexate therapy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Treon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chabner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1322" to="1329" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Doki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Homma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="44" to="49" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Joerger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Huitema</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Van Den Bongard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Clin Pharmacol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="71" to="80" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Interaction between methotrexate and omeprazole in an adolescent with leukemia: A case report</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Bauters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Verlooy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Robays</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharm World Sci</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="316" to="318" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Pharmacokinetic interaction between high-dose methotrexate and amoxycillin</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Ronchera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Peris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ther Drug Monit</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="375" to="379" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen</title>
		<author>
			<persName><forename type="first">A</forename><surname>Thyss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Milano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kubar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="256" to="258" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: A significant number result from unrecognized co-administration of several drugs</title>
		<author>
			<persName><forename type="first">D</forename><surname>De Miguel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Garc</forename><surname>Ia-Su Arez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Mart</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nephrol Dial Transplant</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="3762" to="3766" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">High methotrexate exposure and toxicity in children with t(9;22) positive acute lymphoblastic leukaemia treated with imatinib</title>
		<author>
			<persName><forename type="first">C</forename><surname>Loue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Garnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bertrand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Pharm Ther</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="599" to="600" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Glycyrrhizin and licorice significantly affect the pharmacokinetics of methotrexate in rats</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Hou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Agric Food Chem</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1854" to="1859" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus</title>
		<author>
			<persName><forename type="first">K</forename><surname>Schmiegelow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Attarbaschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Barzilai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="449" to="452" />
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note>Lancet Oncol</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">PharmGKB summary: Methotrexate pathway</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Mikkelsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Thorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenet Genomics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="679" to="686" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Mechanisms of the effects of methotrexate</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Cronstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Merrill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bull Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="6" to="8" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Davidsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dalhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schmiegelow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pediatr Hematol Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="831" to="849" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Polyglutamation of methotrexate. Is methotrexate a prodrug?</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Chabner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Allegra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Curt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="907" to="912" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment</title>
		<author>
			<persName><forename type="first">H</forename><surname>Schrøder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Clausen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ostergaard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="190" to="193" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Methotrexate pharmacokinetics in age-fractionated erythrocytes</title>
		<author>
			<persName><forename type="first">H</forename><surname>Schrøder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="203" to="207" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Methotrexate kinetics in myeloid bone marrow cells and peripheral neutrophils</title>
		<author>
			<persName><forename type="first">H</forename><surname>Schrøder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother Pharmacol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="42" to="46" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Fotoohi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Albertioni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="410" to="426" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
